Nuvation Bio Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Jim Cramer called Nuvation Bio (NUVB) a 'pure spec' on CNBC's Mad Money, warning of high risk due to its reliance on pipeline drugs. The stock surged after FDA granted Fast Track status to its brain cancer drug, Safusidenib, and its lung cancer drug, IBTROZI, became the top prescribed treatment. Analysts expect 113% upside, but Cramer cautions about trial risks. NUVB is expected to post a net loss for 2026.
JPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and a $13 price target, implying 100% upside. The bank cited strong sales of IBTROZI, a lung cancer drug launched in 2026, and potential from safusidenib, an experimental brain tumor drug. Nuvation reported Q2 2026 revenue of $31.7M, beating estimates, but still operating at a loss. The stock has fallen 18% YTD but gained 8% in the past five days.
Nuvation Bio (NUVB) reported that its CSO, Gary Hattersley, exercised options for 100,000 shares at $1.87 each and sold them at $7.0924 per share under a 10b5-1 plan. The sale generated approximately $709K in gross proceeds, with a pre-tax spread of $522K. Hattersley retains 400,000 stock options, vesting over time until 2034.
Over the past 7 days, alphai's AI scored 1 news story mentioning NUVB (Nuvation Bio Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent NUVB coverage spans financial news, market movers and regulation.
In the last 30 days, NUVB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($709K). The most active reporter was Hattersley Gary, CHIEF SCIENTIFIC OFFICER, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Cramer's warning may temper short‑term buying pressure on NUVB.
Analyst upgrade and doubled price target could drive significant upside as the stock trades near $6.5.
The insider sold shares for a $522k pre‑tax spread, indicating confidence to cash out but the amount is modest relative to market cap.
Insider sale by a top executive may signal reduced confidence, potentially pressuring the stock.
Positive regulatory milestone de‑risky development path and supports higher valuation.
alphai scores every news story that mentions NUVB with an AI model for sentiment and relevance, and aggregates insider trades from Nuvation Bio Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jim Cramer called Nuvation Bio (NUVB) a 'pure spec' on CNBC's Mad Money, warning of high risk due to its reliance on pipeline drugs. The stock surged after FDA granted Fast Track status to its brain cancer drug, Safusidenib, and its lung cancer drug, IBTROZI, became the top prescribed treatment. Analysts expect 113% upside, but Cramer cautions about trial risks. NUVB is expected to post a net loss for 2026.
2 min readJPMorgan initiated coverage of Nuvation Bio (NUVB) with an Overweight rating and a $13 price target, implying 100% upside. The bank cited strong sales of IBTROZI, a lung cancer drug launched in 2026, and potential from safusidenib, an experimental brain tumor drug. Nuvation reported Q2 2026 revenue of $31.7M, beating estimates, but still operating at a loss. The stock has fallen 18% YTD but gained 8% in the past five days.
3 min readNuvation Bio (NUVB) reported that its CSO, Gary Hattersley, exercised options for 100,000 shares at $1.87 each and sold them at $7.0924 per share under a 10b5-1 plan. The sale generated approximately $709K in gross proceeds, with a pre-tax spread of $522K. Hattersley retains 400,000 stock options, vesting over time until 2034.
1 min readHattersley Gary (CHIEF SCIENTIFIC OFFICER) sold 100,000 shares of Nuvation Bio Inc. (NUVB) at $7.09 ($0.71M total) on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readNuvation Bio (NUVB) stock rose 2.8% to $7.02 after the FDA granted Fast Track Designation to safusidenib, its therapy for IDH1-mutant glioma, citing Phase 2 study data. Cantor Fitzgerald initiated coverage with an Overweight rating and $12 price target, projecting peak sales of $965M for IBTROZI and $1.9B for safusidenib. The broader market also showed gains.
2 min readAnalysts initiated coverage on five companies. Baird rated Hubbell (HUBB) Outperform with a $550 target. BMO rated Nvidia (NVDA) Outperform with a $340 target. Needham rated Faeth Therapeutics (FTH) Buy with a $56 target. Citizens rated Builders FirstSource (BLDR) Market Perform. Cantor Fitzgerald rated Nuvation Bio (NUVB) Overweight.
1 min readCantor Fitzgerald initiated Nuvation Bio (NYSE:NUVB) with an overweight rating and a $12 price target, citing its two targeted therapies. The firm estimates peak sales of $965M for Ibtrozi and $1.9B for safusidenib. NUVB reported Q2 2026 revenue of $31.7M, beating estimates but with a wider loss per share. The stock is up 149% over the past year.
2 min readNuvation Bio (NUVB) received FDA Fast Track Designation for Safusidenib, an oral therapy for IDH1-mutant glioma. Phase 2 results showed a 51.9% response rate, with ongoing Phase 3 trials. NUVB stock closed at $6.83, up 1.76% overnight.
1 min readJPMorgan initiated coverage of Nuvation Bio with an overweight rating and $13 price target, implying 101% upside. The bank cited early commercial execution of cancer drug IBTROZI and potential revenue growth. Shares rose 1% on Tuesday, up 56% over three months.
2 min readNuvation Bio (NYSE:NUVB) reported Q2 2026 revenue of $31.69 million, up from $4.83 million a year earlier, but its net loss widened to $62.84 million and loss per share from continuing operations was $0.18. The company highlighted long-term Phase 2 TRUST-I and TRUST-II data for IBTROZI (taletrectinib) in ROS1+ NSCLC at major conferences.
4 min read
